GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: TRIUMPH stopped being a problem at week 15 — 42 comments in the full submission. View in context.
2.5k
c/trialwatch·submitted 2 months ago by u/yara_bakken

small win: TRIUMPH stopped being a problem at week 15

Trial Databranch of 8 comments

Something I noticed reading old threads that I have not seen said out loud. The advice on SURMOUNT in this community changed substantially around the start of last year, and nobody went back and updated the older posts. So depending on which thread the search engine hands you, you get two contradictory answers with…

Read the full submission and all 42 comments →

This branch

8 comments, started 1 months ago
u/milos_vanhecke251 points·1 months ago

Every time this gets posted it hits the front page and every time someone has to re-explain it.

replysharereportpermalink
u/hamza_weiss167 points·1 months ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/yara_bakkenOP95 points·1 months ago

Small correction: the trial was 18 weeks, not 14. Does not change your point but people will quote it.

replysharereportpermalink
[removed]70 points·1 months ago

[removed by moderator]

replysharereportpermalink
u/yara_bakkenOP35 points·1 months ago

Not convinced. The evidence does not support that reading.

replysharereportpermalink
u/hugo_norgaard195 points·1 months ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/anders_kuusela129 points·1 months ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/tb500_tangent28 points·1 months ago

Sceptical. If this were true we would see it reflected in the data and we do not.

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →